Total anomalous pulmonary venous return (TAPVR) is a congenital heart defect inherited via complex genetic and/or environmental factors. We report detailed mapping in extended TAPVR kindreds and mutation analysis in TAPVR patients that implicate the PDGFRA gene in the development of TAPVR. Gene expression studies in mouse and chick embryos for both the Pdgfra receptor and its ligand Pdgf-a show temporal and spatial patterns consistent with a role in pulmonary vein (PV) development. We used an in ovo function blocking assay in chick and a conditional knockout approach in mouse to knock down Pdgfra expression in the developing venous pole during the period of PV formation. We observed that loss of PDGFRA function in both organisms causes TAPVR with low penetrance (∼7%) reminiscent of that observed in our human TAPVR kindreds. Intermediate inflow tract anomalies occurred in a higher percentage of embryos (∼30%), suggesting that TAPVR occurs at one end of a spectrum of defects. We show that the anomalous pulmonary venous connection seen in chick and mouse is highly similar to TAPVR discovered in an abnormal early stage embryo from the Kyoto human embryo collection. Whereas the embryology of the normal venous pole and PV is becoming understood, little is known about the embryogenesis or molecular pathogenesis of TAPVR. These models of TAPVR provide important insight into the pathogenesis of PV defects. Taken together, these data from human genetics and animal models support a role for PDGF-signaling in normal PV development, and in the pathogenesis of TAPVR.
INTRODUCTION
The majority of congenital heart defects (CHD) have a complex 'multifactorial' etiology, occurring because of the interplay of multiple moderate or low-risk alleles with environmental factors. One such defect, called total anomalous pulmonary venous return (TAPVR), is a life-threatening CHD that affects 1 in 15 000 live births (1) . In TAPVR, the four pulmonary veins (PVs) that normally return oxygenated blood to the left atrium (LA) are anomalously connected to the systemic venous system. Although numerous reports have addressed the normal embryology of the PVs, almost nothing is known about the molecular pathogenesis of isolated TAPVR or other anomalies of the human PV.
We previously mapped a susceptibility gene for TAPVR to the centromere of human chromosome 4 by linkage analysis (2, 3) . Using unique genealogical resources in Utah, we subsequently discovered that many TAPVR-affected individuals are related via multiple unaffected carriers, and we hypothesized that TAPVR in these families occurs in part because of a genetic susceptibility inherited from distant common ancestors. We reported a founder effect haplotype in one such extended family that localized the TAPVR-1 gene to a 2.4 Mb portion of human chromosome 4q12 (4). Here we report further delineation of these extended families and detailed single nucleotide polymorphism (SNP) mapping that limits the TAPVR-1 interval to the intergenic region between the PDGFRA (platelet-derived growth factor receptor alpha) and KIT genes, implicating a defect in gene regulation. Further, we found relatedness between both parents of several TAPVR parents as well as a region of homozygous shared haplotypes that suggests a requirement for two mutant regulatory alleles at this locus, in combination with other genetic (tri-allelic) or environmental factors, in the development of TAPVR. Finally, mutation analysis of the PDGFRA gene in TAPVR patients reveals a rare sequence variant that points to this gene as a putative TAPVR gene.
We hypothesized that TAPVR might result in part from perturbations in the regulation of PDGFRA expression or from PDGFRA dysfunction during PV formation. The complex mechanisms that underlie the embryonic segregation of the PV from the remainder of the systemic venous system have been extensively studied (5 -20) . Although the precise origin of the PV has been controversial, central to the process of partitioning the PV from the systemic venous system is a tissue of extracardiac origin called the dorsal mesocardial protrusion (DMP), also known as the spina vestibuli (5,13,16,19 -24) . This population of extracardiac mesenchyme arises from the second heart field (SHF; 25) and gains access to the venous pole of the heart through a remnant of the dorsal mesocardium that remains connected to the inflow end of the heart. Cells of the DMP grow towards the inferior cardiac cushion and contribute to portions of the atrioventricular septal complex (AVSC) that, in part, partitions the venous system into systemic and pulmonary circulations (13, 20, 21, 23, 26) . Developmental abnormalities of the DMP in mice with abnormal sonic hedgehog signaling (21, 26) result in atrioventricular (AV) septation defects. Podoplanin mutant-mice have DMP abnormalities with both AV septal defects and deficient PV myocardium (10) . Despite the growing body of knowledge regarding the role of the DMP in inflow tract development, no human inflow tract abnormalities have been linked to mutations in genes or pathways known to be involved in DMP formation. Here we report that the chick and mouse homologs of the human PDGFRA gene, located near the shared TAPVR-1 interval on human 4q12, are expressed in the DMP during critical periods of PV development. We show that knock down of PDGFRA function in these animal models results in a spectrum of inflow tract defects including TAPVR. Finally, we present an example of TAPVR in a 6-week human embryo that closely resembles TAPVR found in the model organisms.
RESULTS

Identity by descent mapping narrows the TAPVR-1 interval
Using genealogical data in the Utah Population Database, we identified two extended kindreds (Fig. 1A) in which multiple TAPVR patients are related via deep ancestral loops through multiple unaffected individuals. All related patients in these two kindreds are affected with isolated non-syndromic TAPVR. One kindred, shown in Figure 1 as red lines, has 20 TAPVR affected individuals [see Bleyl et al. 2006 (4) for full pedigree] and spans more than 14 generations. Since our previous report, we found that two affected individuals in this kindred are also related through their 'marry in' parents via a separate 9-generation ancestral loop (shown as blue lines). Similarly, a second extended kindred is clustered around individual 5-03 who is related to TAPVR patients through both parents (yellow and green lines). We previously noted an extended short tandem repeat (STR) haplotype shared between individuals 5-03 and 3-06, which is confirmed by the SNP analysis, discussed below, suggesting an unknown common ancestor. We hypothesized that these extended kindreds share haplotypes within the TAPVR-1 interval, inherited from common founder ancestors (identical by descent) that confer a susceptibility to the development of TAPVR.
To test this hypothesis, we compared phased haplotypes for 92-tag SNPs across the centromeric end of the Scottish founder interval where we had noted STR haplotypes sharing. Within this region we discovered intervals that were identical by descent in TAPVR patients from both extended kindreds (Fig. 1B) . The original Scottish founder effect was verified by this analysis and the position of the centromeric recombination event was localized near D4S1630. An identical SNP haplotype spanning 665 kb (based on additional STR mapping) is shared by individuals 5-03 and 3-06 and overlaps the centromeric end of the Scottish founder interval. Individual 5-03 also inherits a separate, large haplotype shared with individual 5-22. These larger haplotypes span multiple blocks of linkage disequilibrium and were not observed in 120 CEPH (Center for the Study of Human Polymorphisms) haplotypes, strongly supporting that they were inherited from a common ancestor. Overlap between these larger shared haplotypes defines the likely location of the TAPVR-1 susceptibility interval to the PDGFRA-KIT intergenic region (Fig. 1B) .
As indicated in Figure 1B , smaller haplotypes are shared between related individuals in each kindred. As the length of these haplotypes decreases, their significance becomes less clear and consensus for measuring the statistical significance for small shared haplotypes is lacking. However, within the smallest region of overlapping haplotypes all TAPVR patients in both kindreds (14/14) are homozygous for an identical four-SNP haplotype that spans 16 kb. In contrast, homozygosity for this four-SNP haplotype was observed to be near 30% in the 120-CEPH haplotypes, in 254 unrelated Utah controls and in 23 unrelated TAPVR patients ( Fig. 2A) . Autosomal recessive inheritance of TAPVR is ruled out by the observation that this four-SNP haplotype is inherited in the homozygous state by three unaffected siblings of TAPVR patients. Within this 16 kb region shared in the homozygous state by all TAPVR patients are six conserved non-coding (CNC) regions that may represent regulatory elements.
Resequencing of PDGFRA identifies a TAPVR-associated rare variant
Based on the proximity of the PDGFRA gene to the interval shared by TAPVR families, we hypothesized that functional variants in the gene, particularly in unlinked patients, might contribute to the occurrence of TAPVR. To test this we sequenced the coding region of the PDGFRA gene in the sporadic patients, and in a subset of familial TAPVR patients (indicated in Fig. 2) .
We found a G to A missense mutation in exon 9 that results in the substitution of a glycine residue at position 429 with an arginine (G429R) in two of the 27 unrelated TAPVR patients and in the one available unaffected parent tested. This variant is not reported in dbSNP but was found in two out of 600 ethnically matched control individuals screened (one out of 600 chromosomes for a frequency of 0.0017), occurring at an increased rate in our TAPVR patient cohort (Fisher's exact 1 -14) are also related through their 'marry in' parent (shown with a blue line) to an English common ancestor. Similarly, other TAPVR affected individuals were related through multiple non-penetrant obligate carriers (shown as diamonds with a central dot). Patient 5-03 is related to other TAPVR patients through both parents (solid green and yellow lines). His relationship to patient 3-06, shown with a yellow dashed line, is assumed due to sharing of an extended identical haplotype (.665 kb). In each extended family, the number of meioses separating TAPVR patients is shown with a number. (B) Identity by descent mapping in these kindreds was performed using 92-Tag SNPs chosen using Haploview (4.0) that capture 94% of alleles at r 2 ! 0.8. Shared phased haplotypes are shown as colored boxes. Caucasian linkage disequilibrium (CEU LD) across the region is displayed at the left. Sharing that extends beyond the region (based on STR mapping) is indicated with arrows. Overlap between haplotypes not observed in 120 CEPH haplotypes (marked with asterisks) limits the TAPVR-1 susceptibility to the PDGFRA-KIT intergenic region (shown by a gray bar), implicating mutations in a regulatory element as the susceptibility factor for TAPVR in these kindreds. Smaller regions of overlap are shown, as these focused our attention on the 50 kb interval, marked with dashed lines, discussed in Figure 2 .
two-tailed P ¼ 0.01). We also found eight other SNPs that occur in 5% or more of controls and are not predicted to be deleterious (Fig. 2B) .
Glycine 429 is conserved in vertebrates down to, but not including, fish, but it is not located in a known functional domain of the protein. While the impact of the G429R variant based on PolyPhen or SIFT was predicted to be benign or tolerated, respectively; PANTHER supported the possibility of a deleterious effect. PANTHER calculates a substitution position-specific evolutionary conservation (subPSEC) score (27) that ranges from 0 (neutral) to 210 (most deleterious) and a probability that a substitution is deleterious (P deleterious ). A subPSEC score of 23.0 corresponds to a P deleterious of 0.5 and can be used as a cut-off for a predicted deleterious effect (28) . The subPSEC for G429R is 23.64 with a P deleterious ¼ 0.66. These suggest a low or moderate deleterious effect.
Pdgfra and Pdgf-a are expressed during PV development
The TAPVR-1 region described above contains no known translated genes, implicating dysregulation of a neighboring gene(s) in the occurrence of TAPVR. Based on the genetic data suggesting that PDGFRA may be involved in PV development, we performed gene expression analysis of the embryonic venous pole and dorsal mesocardium in mouse and chick embryos. As shown in Figure 3A and B, the PV is segregated from the systemic venous system by fusion of the DMP to the rest of the AV septal complex. This segregation is complete by E11.5 in mouse or Hamburger and Hamilton stages (HH) 26 in chick (29) .
We examined the expression of the Pdgfra and its ligand Pdgf-a in chick embryos at early stages of PV development. Pdgfra is first expressed in the chick dorsal mesocardium at HH18 (Fig. 3C) , while Pdgf-a is expressed in the adjoining LA. The Pdgfra expression in the dorsal mesocardium occurs in mesenchyme to the right of the PV that is consistent with the location of the DMP. Later at HH19, Pdgfra expression continues to the right of the PV, while Pdgf-a is expressed in cells surrounding the PV.
Pdgfra and Pdgf-a expression at later stages of development were examined in mouse embryos. Pdgfra is expressed in the DMP adjacent to its fusion to the anterior inflow tract wall and the AVSC. At all stages, Pdgf-a expression abuts but does not overlap Pdgfra expression. PDGF-signaling presumably would occur at the interface of these expression domains to the right of the PV in DMP. The expression data suggest a model in which asymmetric PDGF-signaling in the dorsal mesocardium, specifically in the DMP, causes the leftward shift and partitioning of the PV to the LA (Fig. 3C ).
PDGF-blockade is associated with TAPVR in chick
The receptor tyrosine kinase (RTK) blocking drug Imatinib (STI-571), which competitively inhibits ATP binding and in turn RTK activity, was used to block PDGF-signaling (30,31) during chick PV formation in ovo. Imatinib solution was applied in seven separate experiments, using a total of 45-350 mg in three divided doses every 8 h starting at HH15. Embryos were examined at 5 days of development (HH26). Survival of treated embryos was reduced in a dosedependent manner ranging from 70% at low doses to 15% at high dose. Of 79 embryos treated, 32 survived (compared to 30 of 36 controls). Imatinib treatment also resulted in a consistent number of embryos with TAPVR ( Fig. 4A ). Of survivors, 8 (25%) had TAPVR, as revealed by serial sectioning and reconstruction ( Fig. 4B and C) consisting of anomalous connection of the PV to the sinus venosus (SV). TAPVR was never observed in control embryos treated with saline/ antibiotics (n . 50). Imatinib-treated embryos had a dosedependent incidence of other defects that are also seen in PDGFRA-deficient mice (32 -36) . These included neural tube defects, body wall defects and hemorrhages, suggesting that PDGF-signaling is being inhibited. Imatinib also blocks other RTKs including PDGFRB and the KIT proto-oncogene with approximately the same potency (31, 37) , the gene encoding the latter is also found near the TAPVR-1 interval. The use of alternative function blocking agents (anti-PDGFa antibody, truncated PDGFRA and other RTK blockers) into developing chick embryos in ovo proved ineffective, presumably because of poor penetration or limited water solubility (data not shown). Although these experiments do not exclude the possibility that TAPVR in chick results from Imatinib blockade of Figure 1 . Homozygosity was seen for these SNPs across a 20 kb interval in all available TAPVR affected individuals (14/ 14) from the two extended kindreds in Figure 1A . In contrast, homozygosity of these four markers was seen in 8/23 (34%) unlinked familial or sporadic TAPVR patients. This is similar to the frequency of homozygosity found in ethnically matched Utah controls (77/254 or 30%) shown in gray. (B) Resequencing of the PDGFRA gene in 27 TAPVR patients (indicated by þ sign in A) identifies a G to A change in exon 9 that results in substitution of glycine 429 with an arginine in patients 8-03 and I-7. Other previously identified variants (listed by rs number) were also found in TAPVR patients. a non-PDGFRA RTK, these encouraging results led us to examine a Pdgfra-deficient mouse model.
Inflow tract abnormalities in Pdgfra-deficient mouse embryos
Both null and conditional ('floxed') alleles for the mouse Pdgfra gene (34, 36) were obtained, and were used to observe the effects that a range of PDGFRA dosage, from If this fusion is incomplete, the pulmonary venous return may remain connected to the systemic venous drainage resulting in anomalous pulmonary venous return. (C) At HH17 in chick, a single midline PV (asterisks) forms in the dorsal mesocardium, which continues to connect the inflow end of the heart to the gut. In chick, during HH18 and HH19, the PV becomes shifted to the LA by proliferating cells of the DMP that express Pdgfra. The Pdgf-a ligand is expressed to the left of the DMP in cells surrounding the PV. At later stages (E11.5 mouse) Pdgfra and Pdgf-a continue to be expressed in the DMP as it expands into the venous pole and fuses to the IAVC and anterior inflow wall. A fusion plane (shown with a yellow dashed line) can be seen between the Pdgfra expressing DMP and the anterolateral inflow wall. All panels are shown as Â10 magnification. L, left common cardinal vein; S, sinus venosus. patterns). We also examined embryos after temporally restricted deficiency using a Cre-ER driver (40) to universally knock down PDGFRA after the period of early lethality. Because lethality continued to be a problem as development progressed in all of the above mutations, the PV connection was assessed at E11.5 -12.5.
In 103 Pdgfra-deficient embryos (29 Pdgfra null/null and 74 conditionally deficient embryos), we observed TAPVR as a consistent but rare phenotype, occurring in seven (7%) mutants (Table 1) . We did not observe TAPVR in any of 68 control littermates examined (wild-type, Pdgfra null/þ, flox/þ or flox/flox ). As shown in Figure 5 , the TAPVR presented as a persistent connection of the pulmonary venous ostium to the systemic venous system beyond E11.5, when this connection is normally absent. In most embryos found to have TAPVR, the anomalous connection was to the SV as demonstrated by the three-dimensional reconstruction in Figure 5D and was similar to the abnormal PV connections observed in Imatinibtreated chick embryos. A single E13.5 embryo had a blind-ended PV (see below).
Although there was a low rate of TAPVR in the Pdgfra mutants, there was a higher rate of intermediate inflow tract defects. The most common defects were double supra-hepatic inferior vena cavae (IVC) and inferior fusion defects of the DMP resulting in 'notching' of the inferior portion of the DMP (Fig. 6A and B ) compared with the normal inferior portion of the DMP (Fig. 6C) . This notching was variable in depth, and in some cases nearly allowed communication of the PV to SV (i.e. TAPVR, see Fig. 6B ). A second IVC, which could represent a persistent left vitelline vein, was often found directly posterior to these notches. The double IVC was usually seen in embryos with TAPVR, suggesting that a notched DMP and TAPVR lie within a spectrum of inflow tract defects. The Pdgfra null/null embryos often had hypoplastic DMP (Fig. 6D) and double IVC. Of note, embryos with laterality defects of the heart (strongly associated with TAPVR in humans) often had double supra-hepatic IVC as demonstrated by a Pitx2 dASE/dASE (41) embryo (Fig. 6E) with right atrial and pulmonary isomerism, TAPVR and double supra-hepatic IVC.
Whereas the majority of our observations were done in mouse at E12.5, several E13.5 and E15.5 Pdgfra null/null embryos survived. The morphology and development of their PV, left atrial dorsal wall and atrial septum were compared with wild-type embryos. In two of the three E13.5 Pdgfra null/null embryos, the PV drained normally to the LA. However, in one mutant, the common PV ended blindly at the base of the atrial septum and the left and right PVs were hypoplastic (Fig. 7A -F) . Both atria were smaller in the mutant embryos (Fig. 7B ) and the lungs of this embryo were also hypoplastic.
Two E15.5 Pdgfra null/null mutants were examined. In one of the embryos, the right PV was absent and the left PV was hypoplastic (Fig. 8B) . In this mutant embryo we observed an atrial septal defect and both atria were small (Fig. 8B) . The position of the PV was more caudal when compared with the control heart. It seemed that the complete sinus venous was not well incorporated. The connection of the PV was, however, to the left side of the defective atrial septum (Fig. 8A and B) . The right lung of the mutant embryo was severely underdeveloped compared with the left lung and with lungs of the controls.
In these later stage embryos, we examined the expression of atrial myosin light chain 2 (MLC2a), which normally stains the myocardium of the atria and the PV myocardial cuff (9) . The expression in the atrial myocardium was comparable in the mutant and control embryos (Fig. 7C-F) . However, myocardial MLC2a staining around the hypoplastic PV in the mutant was greatly reduced (Supplementary Material, Fig. S3 ). The 1A4-staining of the smooth muscle cells (SMCs) of the media of the PV that normally extends into the LA dorsal wall (9) (Fig. 8C and E) was also reduced in the Pdgfra null/null embryos ( Fig. 8D and F ).
Normal and abnormal human PV development
Our studies of both normal and abnormal development in mouse and chick embryos revealed remarkably similar PV and DMP morphology. To address whether our findings could be generalized to humans, we examined serial sections of normal and abnormal human embryos in the Kyoto Collection of Human Embryos (42) . As shown in Figure 9 , the PV and DMP of a normal 6-week (Carnegie stage 17) human embryo are highly similar to that of either mouse or chick of equivalent stage. We identified a single human embryo in the collection with TAPVR. This embryo (Kyoto embryo number 50445) was noted to have right pharyngeal arch anomalies externally (Fig. 9A -D) . Comparing sections of this embryo with those of a normal embryo revealed that the PV was connected to the SV and had an under-developed DMP similar to those seen in our mouse and chick studies ( Fig. 9E and F) . Serial three-dimensional reconstructions comparing these embryos (Fig. 9G -J ) confirmed TAPVR and inferior deficiency, and failed inferior fusion of the DMP with the AV cushions (also see three-dimensional reconstructions in Supplementary Material, Fig. S4 ).
DISCUSSION
The inheritance of most CHDs, including TAPVR, is complex and likely occurs because of the interplay of multiple low or moderate risk genetic and environmental factors. Discovery of causative genes for such defects in human studies is complicated by genetic heterogeneity and reduced or variable penetrance. Similar difficulties are seen in animal studies, where molecular redundancy may mask the effects of a mutation in a model organism that would be significant to a human patient. Because of these complexities we have used an integrated human genetic and animal model approach to study the genetic TAPVR susceptibilities located at human 4q12. Figure S2A ,B for three-dimensional PDF files of the above reconstructions. RA, right atrium (dark blue). Identity by descent mapping in extended Utah families limits the TAPVR-1 susceptibility locus to the PDGFRA-KIT intergenic interval based on large overlapping haplotypes. Within this interval, we identified a 16 kb interval carried in a homozygous state by all 14 related TAPVR patients in the two extended kindreds. Based on this result we propose a model in which two copies of a mutation affecting the regulation of PDGFRA in the shared homozygous interval are required for the development of TAPVR. Because several siblings of TAPVR-affected patients also inherit two copies of the same haplotype, additional factors seem to be required, raising the possibility of tri-allelic inheritance. The study did not rule out the possibility that other genes in the region, including KIT, are also involved in PV development or in TAPVR. However, identification of a possible functional variant in PDGFRA in two unrelated TAPVR patients focused our attention on this gene.
The significance of the rare G429R variant is unclear. However, its increased occurrence in TAPVR patients as well as the overall conservation of glycine at residue 429, as measured by PANTHER, suggests that the variant could have functional significance. The possibility that G429R is a low-to moderate-risk susceptibility allele fits with the idea that TAPVR occurs because of a combination of genetic . Sections through the embryonic heart are shown at the level of the venous pole for a normal human embryo (E) and for the abnormal embryo (F). In the normal case, the PV is seen deeply invested in the DMP, but in the abnormal embryo the PV drains into the SV. Posterior views of three-dimensional reconstructions from the normal (G) and abnormal (H) embryos are shown. In the normal case, the PV enters the floor of the LA, whereas the PV in the abnormal embryo enters the SV. Sections (indicated by red lines) of these reconstructions viewed superiorly are shown. In the normal embryo (I) the PV ostium is seen in the floor of the LA to the left of the interatrial septum (IAS) that has fused to the endocardial cushions (CUS). The PV ostium in the abnormal case (J) is seen entering the SV and the inferior extent of the IAS (capped with yellow cushion tissue and marked with an asterisk) has not fused to the endocardial cushions. See Supplementary Material, Figure S4 for three-dimensional PDF files of the above reconstructions. RAV, right anterior cardinal vein; LAV, left anterior cardinal vein; RA, right atrium; CS, coronary sinus.
factors. We would expect to find such alleles in unaffected parents and rarely in the population, as is seen for G429R. However, the possibility that G429R is a rare variant without functional significance remains pending functional studies of this mutation.
Our chick and mouse studies show expression of Pdgfra and its ligand Pdgf-a at the venous pole during critical periods of PV development in the location consistent with the DMP. Questions about which cell populations in the DMP express Pdgfra, and about the function of the gene in these cells are under evaluation. However, this temporal and spatial expression pattern is highly suggestive of a role in PV development, especially when combined with functional studies in both chick and mouse embryos that result in anomalous PV connection.
The finding that knockdown of PDGFRA in mouse, even in PDGFRa null mice, leads to TAPVR with low-penetrance agrees with our human genetic studies. In our human kindreds, TAPVR occurs with reduced penetrance even in individuals presumed to be homozygous for a susceptibility allele implying the involvement of other genetic or environmental factors. This reduced penetrance may be owing to stochastic effects. However, the use of non-inbred strains may indicate variable penetrance based on genetic differences and may, therefore, offer an opportunity to identify genetic and/or environmental factors that influence the penetrance of TAPVR.
These, the first animal models of non-laterality-related TAPVR, give insight into the pathogenic mechanisms of the defect during embryogenesis. Based on the expression pattern of Pdgfra and on the morphology of the mutant embryos with TAPVR, we propose a model in which TAPVR occurs as a result of failed outgrowth and/or fusion of the DMP with the anterior inflow tract wall and the AVSC. Of the chick and mouse embryos observed at HH26 and E12.5, respectively, all had TAPVR with anomalous connection to the SV. Our study does not directly investigate the origin of the PV connection to the venous pole. However, this result could be interpreted as a persistent connection to the SV, supporting the view that the common PV is connected to the SV early in development (6, 7, 16) . In this view, growth of the DMP, which contributes to and fuses with the AVSC, separates the part of the SV receiving the common PV from the part connected to the systemic veins. Because Pdgfra-deficient embryos have a hypoplastic DMP, the wedge of cells between the left and right atrial appendages is incomplete, allowing a persistent PV connection to the SV. An alternative interpretation would be an anomalous connection to the SV instead of an initial connection to the left atrial segment, a view summarized by Wessels and co-workers in 2006 (20) . Future study of these mutants will help in differentiating between these possibilities.
Despite the use of a conditional approach, most Pdgfradeficient embryos die before the PVs reached their final configuration. However, anomalous connection to the SV in the vicinity of the common cardinal vein could, with differential growth, result in a variety of anomalous PV connections similar to those seen in human TAPVR. In addition, the existence of what we propose is a persistent left vitelline vein (Fig. 6 ) and alignment of this vessel with the PV (Fig. 5 ) may represent the mechanism of infradiaphragmatic pulmonary venous connection. As we previously reported (4), none of the obligate gene carriers in either kindred have intermediate defects analogous to double supra-hepatic IVC seen in the mouse. However, TAPVR is itself a spectrum of defects with variability in the site of anomalous PV connection (supracardiac, cardiac, infradiaphragmatic, etc.) and this variability may be explained by the degree or site of DMP deficiency during human development.
During differentiation, the wall of the PV acquires a media of SMCs and a small adventitia, underneath an endothelial layer, which is all covered by a myocardial cuff. The cell population that is responsible for the origin of both the SMCs as well as the myocardial cuff is under debate but there are indications that both derive from the SHF mesoderm (9, 13) . To distinguish between the SMCs and the myocardium by immunohistochemistry using alpha smooth muscle actin is possible only after the myocardium loses this staining quality. It has been shown that during normal development the media of the PV extends into the left atrial cavity (8, 9) . With deficient development of the SHF, defective PV wall development and a diminished contribution of SMC in the atrial cavity can be expected as was described for the podoplanin2/2 mouse (9). A diminished contribution from the SHF can also explain the lack of the PV myocardialization as described in patients with TAPVR (43) . In the Pdgfra null/null model we see a similar phenomenon with deficient contribution of SMC in the wall of the LA (Fig. 8) and lack of the myocardial cuff surrounding the PV (Supplementary Material, Fig. S3 ).
Another SHF-derived structure that is abnormal in the Pdgfra mutants is the DMP. The low penetrance observed in Pdgfra mutants currently limits our ability to analyze the specific cellular requirements for PDGF-signaling during PV and DMP development. However, work in other mouse mutants has demonstrated a requirement for Hedgehog (Hh) signaling in the SHF for normal DMP development (21, 26) . DMP progenitors are induced in the SHF by Hh ligand, likely originating in the pulmonary endoderm (26) . In embryos with defective Hh signaling, the DMP fails to form or is hypoplastic due either to failure of this migration (21) or to failure of cell specification (26) . Similarities in the DMP abnormalities seen in these Hh-deficient embryos to those in Pdgfra mutants, as well as deficient PV myocardialization and reduced SMC in the LA wall may all be explained by a role for PDGF-signaling in the process of SHF contributions to the venous pole.
We observed left-sided expression of Pdgf-a in the atrium (Fig. 3C ) and the gut (not shown) of chick embryos that is reminiscent of the expression pattern of the Pitx2 gene, which is involved in left -right asymmetric morphogenesis. We also saw overlap in the inflow tract defects occurring in Pdgfra and Pitx2 mutants, both of which have double suprahepatic IVC (Fig. 6 ) and TAPVR. These findings raise the possibility that Pdgf-a is a downstream target of Pitx2, a prospect that will be explored in future studies.
Although the adult configuration of the human and mouse PVs are different, the mouse having a single common PV entering the atrium (19) as opposed to the usual four veins in humans, the morphology of the PV at early stages is remarkably similar between species (compare Figs 5 and 9 ). We also demonstrate similarities in PV abnormalities between species. As opposed to patients in our TAPVR families, the human embryo with TAPVR we present has defects in addition to anomalous PV connection, and the underlying basis of these abnormalities is not known. However, the morphological appearance of the PV entering the SV in all three species examined is highly similar.
In summary, our data support a role for PDGF-signaling in PV development and suggest that dysregulation of the PDGFRA gene confers susceptibility to the occurrence of TAPVR. Starting from studies of extended family structure and linkage mapping, we have made significant progress in unraveling the inheritance of a CHD previously thought to be poorly heritable, and we have developed animal models that promise to enhance our understanding of these defects in the future.
MATERIALS AND METHODS
Identity by descent mapping
Identification and phenotyping of TAPVR patients, as well as collection of DNA and family history data of TAPVR patients and kindreds was done with informed consent as previously described (4) in accordance with the University of Utah Institutional Review Board (IRB). Extended family relationships were established using computerized ancestry searches through the Utah Population Database (UPDB). Healthy Utahans with northern European ancestry were collected as controls with informed consent and approval of the IRB.
Tag SNPs were selected to span the proximal portion of the TAPVR-1 interval based on STR haplotype sharing (data not shown). 96-Tag SNPs were selected using Haploview (Version 4.0) with parameters set to detect 94% of alleles at r 2 . 0.8. Genotyping of patients and unaffected relatives in the TAPVR families and in 254 ethnically similar Utah controls was done using a custom GoldenGate 96-plex SNP genotyping panel performed on a BeadXpress reader and analyzed using BeadStudio software, version 3.3 (Illumina, Inc.) according to manufacturer protocols. Four SNPs were excluded from the haplotype analysis owing to more than 10% failed genotype calls. Genotypes were exported to Microsoft Excel (Version 12.1.3, Microsoft Corp.) and phased haplotypes were determined for TAPVR kindreds using nuclear-family data. Haplotypes shared between related TAPVR individuals were compared with phased haplotypes from 60 CEPH individuals available in the HapMap dataset (www.hapmap.org). The four-SNP homozygous haplotype found in all 14 related TAPVR patients was compared with unphased genotypes from 254 Utah controls.
PDGFRA resequencing
Polymerase chain reaction (PCR) primers (available on request) were designed to amplify all 23 exons and a portion of each flanking intron of the PDGFRA gene and used to amplify genomic DNA from 27 TAPVR patients. PCR products were subjected to mass spectroscopy mutation detection (GeneMass, Inc., Salt Lake City, UT, USA). Amplicons with masses differing from wild-type were sequenced in both directions using BigDyew Terminator version 3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) on an ABI 3730 machine. The impact of non-synonymous variants was assessed using PolyPhen (http://genetics.bwh. harvard.edu/pph/), SIFT (http://sift.jcvi.org/) and PANTHER (http://www.pantherdb.org/). The frequency of the G429R variant was assessed in 600 unrelated ethnically similar CEPH individuals using a custom TaqMan SNP detection assay with analysis on ABI 7900HT RT -PCR system according to manufacturer specifications.
In situ hybridization
Section in situ hybridization was performed on transversesectioned chicken Hamburger and Hamilton stages (HH) 15-19 and mouse E9.5 -E11.5 embryos using anti-sense digoxigenin-labeled riboprobes as previously described (44, 45) . Probes were synthesized from chick and mouse Pdgfra clones (ChEST55k2; IMAGE:5704645) and from chick and mouse Pdgf-a ligand clones (ChEST826l7; IMAGE:3495629). Cover-slipped sections were imaged on a Nikon compound microscope using a QImaging chargecoupled device camera with QCapture software (QImaging, Burnaby, Canada).
Pdgfra inhibition in chick
The RTK inhibitor Imatinib (STI571/Gleevec, Novartis Pharma AG, Switzerland) was used for PDGFRA inhibition experiments (30, 31) . Imatinib tablets (100 mg) were dissolved in sterile saline with penicillin and streptomycin at room temperature, filtered and diluted to a 0.125 -0.5 mg/ml working solution. Fertilized eggs were windowed at HH15 and treated with three doses of RTK inhibitors at 8-h intervals. In separate experiments, 200 ml of Imatinib solution was added directly on top of the vitelline membrane at doses of 45, 75, 90, 150, 275 and 350 mg. Control embryos were treated with saline/ antibiotic. For all in ovo inhibition experiments, embryos were inspected under a dissecting microscope at each dose for viability, achieving the correct stage of development and abnormalities. After treatments, embryos were incubated an additional 48-56 h in ovo until 5 days of development (HH26). They were then sacrificed, examined for external defects, photographed and fixed in modified Bodian's fixative at 48C overnight.
Mouse lines and matings
The Pdgfra null/null and Pdgfra flox/flox mutant lines have been described previously (34, 36) . The Pdgfra flox/flox mutant contains loxP sites flanking exons 2 -5, resulting in the deletion of these exons in cells expressing Cre-recombinase. This 'floxed' allele contains the neomycin selection cassette and is thought to be a hypomorphic allele because Pdgfra 0 . This results in 300, 450 and 575 bp PCR products for the floxed, wild-type and null alleles, respectively. To avoid the early lethality seen in Pdgfra null/null embryos, the conditional allele was mated to three previously described Cre-driver lines. Both the HoxA3-Cre (38) and Lefty2-Cre (39) driver lines expressed Cre recombinase throughout the dorsal mesocardium by E8.5 but not at E7.5, as assessed by mating to the Rosa26 lacZ reporter line (46) . Cre expression patterns are shown in Supplementary Material, Figure S1 . The R26 Cre-estrogen receptor (ER) fusion driver line (40) was used to express Cre recombinase universally after a single 0.8 mg per 10 g body weight dose of Tamoxifen by oral gavage at E7.5 (47) . A Pdgf-a;LacZ BAC transgenic line (48) was used to visualize the expression of the Pdgf-a gene at E11.5. We compared the phenotypes observed in Pdgfra-mutants with the inflow tract of the Pitx2 dASE/dASE mutants (41) , in which the asymmetric enhancer is disrupted resulting in right atrial isomerism and TAPVR.
Assessment of PV morphology
PV development in all embryos was assessed histologically. A subset of histological sections was further assessed using three-dimensional reconstruction. The majority of embryos (S.B.B. laboratory) were fixed in modified Bodian's fixative and embedded in paraffin. Transverse 10 mm sections were cut from the aortic bifurcation to the base of the ventricle and stained with hematoxylin and eosin (H&E) using standard methods. Later stage wild-type (Swiss background) and Pdgfra null/null embryo of stage E13.5 (n ¼ 3) and E15.5 (n ¼ 2) were fixed in 4% paraformaldehyde and embedded in paraffin (G.D.G laboratory). Transverse 5 mm sections were mounted onto albumin/glycerin-coated glass slides. Immunohistochemistry was performed with antibodies against alpha-smooth-muscle actin (1A4, 1:2000, Sigma Chemical Co. Aldrich, Product No. A2547, USA) and atrial myosin light chain 2 (MLC2a, 1:6000, kindly provided by S.W. Kubalak, Charleston, SC, USA). Stained section of wild-type and Pdgfra null/null embryos were used to make threedimensional reconstructions. The pulmonary venous connection was scored under a dissection microscope at 10X magnification. For serial reconstructions, sections were digitally imaged at Â10 magnification then aligned, segmented and reconstructed using the Amira software package version 5.0 (Visage Imaging, Inc, San Diego, CA, USA). A similar procedure was used to examine HE-stained serial sections of human embryos in the Kyoto Collection of Human Embryos (42) . Human embryonic hearts and PV were examined and photographed at Carnegie stage 17 (week 6).
